Conditioned Stem Cell Extract for Personalized Epigenetic Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional genetic and epigenetic therapies are either too general, modifying epigenetic patterns independently of personalized deregulations, or too specific, limiting modifications to a single DNA site, failing to address the unique epigenetic pathology of each patient effectively.
Innovation Solution
A method involving the preparation of a conditioned stem cell-derived extract by mixing an alcoholic solution with diseased cells, treating normal stem cells with this extract, and culturing the conditioned stem cells to create a cell-free extract that can be used to treat diseased cells, thereby inducing personalized epigenetic modifications and correcting gene expression in diseased cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional genetic and epigenetic therapies are used, then epigenetic patterns can be modified, but the modifications are too general and do not address personalized deregulations in each patient
Solution Approach 1:
The patent applies local quality by targeting specific epigenetic modifications at particular DNA sites rather than applying global epigenetic changes. The therapy identifies and modifies specific epigenetic deregulations unique to each patient's disease state, thereby achieving both precision and personalization simultaneously.
Solution Approach 2:
The patent utilizes parameter changes by adjusting epigenetic parameters (such as DNA methylation, histone modification) at specific locations rather than changing all epigenetic parameters uniformly. This allows the therapy to address personalized epigenetic pathologies while maintaining manufacturing precision through targeted modification.
2Ease of manufacture
If conventional therapies modify epigenetic patterns independently of personalized deregulations, then the treatment process is simplified, but the effectiveness in reversing disease-specific epigenetic changes is reduced
Solution Approach 1:
The patent incorporates feedback mechanisms to identify and respond to patient-specific epigenetic deregulations. By monitoring and adapting to the unique epigenetic profile of each patient, the therapy maintains simplicity in administration while significantly improving reliability in reversing disease-specific changes through personalized feedback-driven modification.
3Manufacturing precision
If therapies are designed to be too specific and limited to a single DNA site, then the precision of modification is improved, but the ability to address multiple epigenetic deregulations in each patient is limited
Solution Approach 1:
The patent applies segmentation by dividing the epigenetic modification process into multiple targeted sites rather than treating it as a single uniform process. Each segment corresponds to a specific DNA site with unique epigenetic deregulation, allowing the therapy to maintain precision at each site while collectively addressing multiple personalized pathologies through systematic segmentation of the modification task.
Data Source
AI summary
A method for modifying gene expression of diseased cells in a patient including preparing an extract of diseased cells, forming a plurality of conditioned stem cells by treating a plurality of normal stem cells with a solution of the extract of the diseased cells with a volume ratio between 10−15 volume/volume (v/v) and 10−3 v/v (volume of the extract of the diseased cells/volume of a culture medium), forming a conditioned stem cell-derived extract, and forming a plurality of healthy cells by treating the diseased cells with the conditioned stem cell-derived extract.